Overall verdict
Buy
7.5/10
1-year performance
+331.73%
Score breakdown
Up 331.7% over 1 year, 89% of the 52-week range.
23 analysts, target +0.2% vs the price.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC ; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial ; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Mark Goldsmith
Founded
2014
Employees
883
Revenue / employee
0 USD
Next earnings
November 5, 2026 (estimated)
Institutional holders
- BlackRock, Inc.6.84%
- FARALLON CAPITAL MANAGEMENT, L.L.C.6.83%
- FMR LLC6.09%
- BAKER BROS. ADVISORS LP5.72%
- Jupiter Topco LLC5.36%
- Darwin Global Management, Ltd.5.31%
- VANGUARD CAPITAL MANAGEMENT LLC4.54%
- VANGUARD PORTFOLIO MANAGEMENT LLC4.14%
- Nextech Invest Ltd.3.80%
- Other institutions63.01%
694 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
224.31 USD
52-week low
42.18 USD
1-year performance
331.73%
Rising
Year-to-date performance
137.56%
Rising
Drawdown
-8.97%
Mild pullback
Position in the 52-week range
89% of range
ROIC -61.3%, ROE -79.1%.
Net margin
—
Sector -15.60%|S&P 12.97%
Gross margin
—
Return on equity (ROE)
-79.09%
Negative
Sector -19.44%|S&P 16.52%
Return on invested capital (ROIC)
-61.35%
Negative
Free cash flow margin (FCF)
—
Revenue to net income
Growth
0.0/10Revenue down 100.0% over 1 year, -100.0% a year over 5.
Revenue (trailing 12 months)
0 USD
Revenue growth (1y)
-100.00%
Declining
Revenue growth (3y)
-100.00%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 29.6x|S&P 23.0x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 23.3x|S&P 14.5x
PEG
—
Sector 0.37|S&P 0.86
Market cap
40.9Md USD
Financial strength
5.8/10Cash covers 330.8% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-105.42%
Net cash
Cash
3.9Md USD
Cash / market cap
9.63%
Solid
Cash / total debt
330.79%
Net cash
Interest coverage
-27.4x
Stretched
Net debt
-2.7Md USD
Equity
2.6Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 199.86 USD
- MM20203.35
- MM50199.83
- MM200142.15
- RSI 1449.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+10.89%
200-day average slope, 3 months
+45.35%
50-day average slope, 1 month
+5.51%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.33 % per day
Volatility change
-36.58%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -9.73 (21) | -9.70 (21) | 183 (22) | -1 825 (7) | -2 034 (18) |
| 2027 | -5.87 (21) | -6.12 (21) | 1 229 (22) | -1 231 (7) | -1 322 (18) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 431 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 7.5 | 6.9 | 59.5Md USD | 36.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.9 % | 33.9 % | ||
| 2 | RVMD | 7.5 | N/A | 40.9Md USD | Not meaningful (loss) | — | -100.0 % | -61.3 % | — | -3.0 % | 331.7 % | ||
| 3 | VRTX | 6.7 | 5.9 | 131Md USD | 30.0x | 34.7 % | 12.0 % | 21.5 % | -0.9x | 2.9 % | 38.4 % | ||
| 4 | REGN | 6.6 | 6.0 | 82.6Md USD | 19.8x | 27.9 % | 16.7 % | 13.0 % | -1.3x | 4.6 % | 40.2 % | ||
| 5 | AMGN | 6.3 | 6.2 | 220Md USD | 25.2x | 22.9 % | 9.8 % | 14.0 % | 2.9x | 4.6 % | 42.2 % | ||
| 6 | ABBV | 6.2 | 5.6 | 468Md USD | 74.9x | 9.7 % | 10.2 % | 10.5 % | 2.2x | 3.9 % | 19.4 % | ||
| 7 | GILD | 5.5 | 4.3 | 188Md USD | Not meaningful (loss) | -10.6 % | 10.7 % | -8.4 % | 1.1x | 6.9 % | 31.0 % | ||
| 8 | CSL | 4.5 | 4.2 | 60.5Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.7 % | -9.7 % | ||
| 9 | MRNA | 2.7 | 1.9 | 72.7Md USD | Not meaningful (loss) | -141.4 % | 2.1 % | -34.8 % | 1.3x | -1.7 % | 654.5 % |
